Anthropic’s chief executive, Dario Amodei, has stated that the company will deliberately decelerate its artificial intelligence development timeline due to safety concerns, delivering a stark warning during a United Nations Security Council session that poorly governed AI could pose an existential danger to humanity. His remarks, delivered via video link on Wednesday, specifically highlighted the risk of malicious actors exploiting AI to engineer biological weapons, as well as the potential for creating systems that spiral beyond the control of their developers.
The announcement marks a significant strategic position for Anthropic as it prepares for a potential initial public offering that could value the firm at nearly one trillion dollars. Amodei urged world governments to establish international safety standards and coordinate efforts to prevent the use of AI in生化 weapon development, framing his company’s slower research pace as a necessary trade-off for mitigating catastrophic risks. This latest appeal follows a roughly 3,800-word essay published earlier this month, in which he laid out a detailed case for imposing constraints on advanced AI research to give scientists adequate time to assess emerging threats.
During his address, Amodei offered a dual assessment of AI’s trajectory, acknowledging its profound benefits while cautioning against its dangers. He noted that rapid advancements are driving tangible progress in health sciences, citing examples where Anthropic’s Claude model has contributed to discoveries in life-science research, including the identification of a novel enzyme system exhibiting CRISPR-like DNA repeat sequences. At the same time, he emphasized that these same capabilities could be turned toward catastrophic ends, pointing to the specific threat of bioterrorism where AI could enable the synthesis of lethal pathogens—a risk that prompted Anthropic to establish a dedicated life-sciences research laboratory. He characterized the moment as “both an opportunity and a challenge for all humanity,” urging collective vigilance.
Positioning the Security Council meeting as a pivotal opportunity for nations to move beyond their differences, Amodei called for a shared response, stating that no single leader, company, or country can tackle this challenge alone. He proposed the creation of an AI safety certification framework and advocated for a global regulatory cooperation structure to support coordinated measures against the weaponization of biotechnology. His stance directly contradicts the approach of the Trump administration, which has dismissed similar international AI coordination efforts as a conspiratorial globalist plot.
The commercial implications of Amodei’s public pledge to slow development are substantial, given that Anthropic and its rival OpenAI are both racing at the forefront of advanced AI models, with each company also reportedly pursuing IPOs at near-trillion-dollar valuations. His earlier essay has already sparked widespread debate in Silicon Valley, drawing endorsements from OpenAI CEO Sam Altman and xAI, the venture led by Elon Musk, while U.S. lawmakers have cited it to push forward legislative discussions on AI safety measures. These developments signal that safety considerations are now shaping market expectations around the pace and regulatory exposure of leading AI enterprises.